Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. (2014)

First Author: Libri V
Attributed to:  Applying epigenetic modifying drugs to treat Friedreich's Ataxia funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(14)60382-2

PubMed Identifier: 24794816

Publication URI: http://europepmc.org/abstract/MED/24794816

Type: Journal Article/Review

Volume: 384

Parent Publication: Lancet (London, England)

Issue: 9942

ISSN: 0140-6736